WVE
Wave Life Sciences Ltd.

2,381
Mkt Cap
$1.12B
Volume
2.47M
52W High
$16.74
52W Low
$5.28
PE Ratio
-7.90
WVE Fundamentals
Price
$7.05
Prev Close
$7.18
Open
$7.23
50D MA
$7.97
Beta
1.36
Avg. Volume
2.45M
EPS (Annual)
-$0.7015
P/B
7.88
Rev/Employee
$376,048.61
Loading...
Loading...
News
all
press releases
Strength Seen in Wave Life Sciences (WVE): Can Its 11.4% Jump Turn into More Strength?
Wave Life Sciences (WVE) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Zacks·14d ago
News Placeholder
More News
News Placeholder
3 Promising Genomics & Synthetic Biology Stocks in Spotlight in 2025
GeneDx, Twist Bioscience and Wave Life Sciences are emerging as key players in the fast-growing genomics and synthetic biology space.
Zacks·1mo ago
News Placeholder
Wave Life Sciences Tumbled 19% Today, But Not Everyone’s Disappointed – Find Out Why
Wave Life Sciences said Wednesday that its therapy WVE-006 successfully edited RNA in all trial participants, producing lasting levels of a key protein tied to lower risks of liver and lung disease after repeat 200 mg doses.
Stocktwits·2mo ago
News Placeholder
Wave Life Sciences (WVE) Reports Q2 Loss, Misses Revenue Estimates
Wave Life Sciences (WVE) delivered earnings and revenue surprises of -6.90% and -31.16%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·3mo ago
News Placeholder
Illumina (ILMN) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Illumina (ILMN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks·3mo ago
News Placeholder
Raymond James bullish on biotech firms on favorable valuation
Investing.com -- Raymond James started coverage on biotechnology companies, rating Avidity Biosciences and Disc Medicine at Strong Buy and assigning Outperform ratings to Dyne Therapeutics, Tectonic Therapeutic, and Wave Life Sciences (NASDAQ:WVE), pointing to a sector-wide opportunity amid “suppressed valuations.”
investing.com·4mo ago
News Placeholder
Geron (GERN) Reports Q1 Loss, Lags Revenue Estimates
chainwire·6mo ago
News Placeholder
Biotech stocks jump as Makary outlines FDA vision, RBC comments
Investing.com -- Biotech stocks climbed Monday after new FDA Commissioner Dr. Marty Makary laid out a clear and collaborative regulatory strategy that analysts say bodes well for drug developers. In his first major interview since taking office, Makary emphasized pragmatic reforms, faster drug approvals, and modernized use of real-world data across the agency.
investing.com·6mo ago
News Placeholder
What's Next: WAVE Life Sciences's Earnings Preview
read more...
Benzinga·1y ago
News Placeholder
Wave Life Sciences Stock Surges On RNA Editing Breakthrough: Retail Turns Extremely Bullish
Retail sentiment was ‘extremely bullish’ (97/100) following the news.
Stocktwits·1y ago

Latest WVE News

View

Advertisement|Remove ads.

Advertisement|Remove ads.